PFIZER INC — Director's Dealing 2019

Sep 19, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: SpringWorks Therapeutics, Inc. (SWTX)
CIK: 0001773427
Period of Report: 2019-09-17

Reporting Person: PFIZER INC (10% Owner)
Reporting Person: Pfizer Ventures (US) LLC (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-09-17	Common Stock	C	978194	—	Acquired	978194	Direct
2019-09-17	Common Stock	C	3039051	—	Acquired	4017245	Direct
2019-09-17	Common Stock	C	526602	—	Acquired	4543847	Direct
2019-09-17	Common Stock	P	50000	$18	Acquired	4593847	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-09-17	Junior Series A Convertible Preferred Stock	$	C	6437500	Disposed		Common Stock (978194)	Direct
2019-09-17	Series A Convertible Preferred Stock	$	C	20000000	Disposed		Common Stock (3039051)	Direct
2019-09-17	Series B Convertible Preferred Stock	$	C	3465571	Disposed		Common Stock (526602)	Direct

Footnotes

F1: Each share of Junior Series A Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 6.5810:1 basis upon the closing of the Issuer's initial public offering for no additional consideration. The Junior Series A Convertible Preferred Stock had no expiration date. Such shares are held of record by Pfizer Inc. ("Pfizer").

F2: Each share of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 6.5810:1 basis upon the closing of the Issuer's initial public offering for no additional consideration. The Series A Convertible Preferred Stock had no expiration date. Such shares are held of record by Pfizer.

F3: Each share of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 6.5810:1 basis upon the closing of the Issuer's initial public offering for no additional consideration. The Series B Convertible Preferred Stock had no expiration date. Such shares are held of record by Pfizer Ventures (US) LLC, a wholly-owned subsidiary of Pfizer ("PVUS").

F4: PVUS purchased such additional shares of Common Stock in the Issuer's initial public offering at the initial public offering price of $18.00 per share.

F5: Each Reporting Person disclaims ownership of securities held by the other Reporting Person, except to the extent of its pecuniary interest therein.